Internet group (who received the letter of invitation)	control group (who did not receive it)	understanding clinical trials - Breast cancer patients participating in a trial on the efficacy of Trastuzumab	8220	8454	Expectations about the results were also similar in both groups: knowing whether the trial yielded useful results (82.2% P=0.633), understanding the treatment received (20.6% P=0.468), and understanding clinical trials (9.3% P=0.745).
Internet group (who received the letter of invitation)	control group (who did not receive it)	knowing whether the trial yielded useful results - Breast cancer patients participating in a trial on the efficacy of Trastuzumab	8220	8454	Expectations about the results were also similar in both groups: knowing whether the trial yielded useful results (82.2% P=0.633), understanding the treatment received (20.6% P=0.468), and understanding clinical trials (9.3% P=0.745).
Internet group (who received the letter of invitation)	control group (who did not receive it)	declared uptake of the trial results - Breast cancer patients participating in a trial on the efficacy of Trastuzumab	1052	1159	The Internet group's declared uptake of the trial results was only slightly higher (47.1% vs 33.9% P=0.166)
Internet group (who received the letter of invitation)	control group (who did not receive it)	accurately understanding the results - Breast cancer patients participating in a trial on the efficacy of Trastuzumab	1052	1252	The Internet group's declared uptake of the trial results was only slightly higher (47.1% vs 33.9% P=0.166); however, they understood the results significantly more accurately (18.8% vs 5.6% P=0.039).
Internet group (who received the letter of invitation)	control group (who did not receive it)	understanding the treatment received - Breast cancer patients participating in a trial on the efficacy of Trastuzumab	8220	8454	Expectations about the results were also similar in both groups: knowing whether the trial yielded useful results (82.2% P=0.633), understanding the treatment received (20.6% P=0.468), and understanding clinical trials (9.3% P=0.745).
